Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 667

Sort by

Sort Order Select

Journal Articles

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

Joseph S. Gish, Lexi Jarvis, Kenneth C. Childers, Shaun C. Peters, Connor S. Garrels, Ian W. Smith, H. Trent Spencer, Christopher B. Doering, Pete Lollar, P. Clint Spiegel, Jr

Blood (2021) 137 (21): 2981–2986.

https://doi.org/10.1182/blood.2020008940

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Anti-FVIII Antibody and Inhibitor Development Patterns in Hemophilia A Mouse Models: A Systematic Review

Sajjad Afraz, MD MSc, George Zhao, Davide Matino, MD MSc, Anthony K.C. Chan, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 2402.

https://doi.org/10.1182/blood-2019-131441

Published: 2019

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5309.

https://doi.org/10.1182/blood-2019-126913

Published: 2019

Journal Articles

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Frederick Fasslrinner, MD, Claudia Arndt, PhD, Anja Feldmann, PhD, Stefanie Koristka, PhD, Liliana Raquel Loureiro, PhD, Marc Schmitz, MD, Gundram Jung, MD, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5614.

https://doi.org/10.1182/blood-2019-124279

Published: 2019

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Amer M Zeidan, MD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux, MD PhD

Blood (2019) 134 (Supplement_1): 4259.

https://doi.org/10.1182/blood-2019-127041

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Ahmad Faisal Karim, PhD, Pooja Vir, PhD, Devi Gunasekera, MBBS, Allen I. Stering, MD, Kenneth Lieuw, MD PhD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 2413.

https://doi.org/10.1182/blood-2019-124803

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia

Jiang Cao, MD, Hai Cheng, MD, Kunming Qi, Wei Chen, Ming Shi, Junnian Zheng, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 3872.

https://doi.org/10.1182/blood-2019-128286

Published: 2019

Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD

Blood (2019) 134 (Supplement_1): 4007.

https://doi.org/10.1182/blood-2019-126670

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Anti-FVIII Antibody and Inhibitor Development Patterns in Hemophilia A Mouse Models: A Systematic Review

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only